4/2
07:00 am
crvo
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
High
Report
Investigators to Present Clinical Trial Results Showing Neflamapimod Slows Clinical Progression in Dementia with Lewy Bodies in Oral Presentation at AD/PD™ 2025
3/26
08:19 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
High
Report
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
3/25
08:00 am
crvo
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
High
Report
CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurologic Disorders (AP/PD™)
3/18
10:36 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Roth Mkm from $15.00 to $20.00. They now have a "buy" rating on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Roth Mkm from $15.00 to $20.00. They now have a "buy" rating on the stock.
3/18
08:05 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $21.00. They now have a "buy" rating on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $12.00 to $21.00. They now have a "buy" rating on the stock.
3/17
10:10 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
3/17
08:00 am
crvo
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
High
Report
CervoMed Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Updates
3/13
12:58 pm
crvo
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Jones Trading from a "hold" rating to a "buy" rating. They now have a $15.00 price target on the stock.
3/13
07:49 am
crvo
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
High
Report
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Chardan Capital from a "neutral" rating to a "buy" rating. They now have a $14.00 price target on the stock.
3/13
06:27 am
crvo
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "strong-buy" rating.
Low
Report
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "strong-buy" rating.
3/11
10:48 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Roth Mkm from $7.00 to $15.00. They now have a "buy" rating on the stock.
High
Report
CervoMed Inc. (NASDAQ: CRVO) had its price target raised by analysts at Roth Mkm from $7.00 to $15.00. They now have a "buy" rating on the stock.
3/11
08:15 am
crvo
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
High
Report
CervoMed Inc. (NASDAQ: CRVO) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $10.00 price target on the stock.
3/10
04:05 pm
crvo
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
Medium
Report
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
2/19
08:00 am
crvo
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at D. Boral Capital from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock.
Medium
Report
CervoMed Inc. (NASDAQ: CRVO) was upgraded by analysts at D. Boral Capital from a "hold" rating to a "buy" rating. They now have a $10.00 price target on the stock.
1/31
08:00 am
crvo
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
Neutral
Report
CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia Conference
1/29
08:00 am
crvo
CervoMed to Present at the 8th International Lewy Body Dementia Conference
Medium
Report
CervoMed to Present at the 8th International Lewy Body Dementia Conference